Artificial intelligence in gastrointestinal health: enhancing detection, diagnosis, and treatment

Deepak [(1)], Joan Vijetha [(2)*], Purushothaman [(3)]

[1, 3] M. Pharmacy, Sathyabama Institute of Science and Technology, Chennai-600119.

[2*] Associate Professor, Sathyabama Institute of Science and Technology, Chennai-600119.

Corresponding author: Dr. Joan Vijetha. R

Associate Professor,Sathyabama Institute of Science and Technology, Chennai-600119.

Mail id: joanvijetha.rnn@gmail.comOrchid ID: 0000-0001-6113-1264

ABSTRACT

The diagnosis and treatment of gastrointestinal (GI) disorders are being revolutionised by the use of artificial intelligence (AI) in gastroenterology traditional techniques for diagnosing gastrointestinal disorders such as radiography pathology and endoscopy have drawbacks such their dependence on operator competence and vulnerability to human error. AI-powered technologies are increasing these operations, speed, accuracy and detection. AI systems improve the accuracy of diagnostic imaging for pancreatic and liver illnesses help find polyps during colonoscopies and analyse histological slides to help detect cancer early AI also facilitates individualised therapy by assessing patient data to create customised treatment regimens particularly for long-term illnesses like liver and inflammatory bowel disease. There are still issues such as the requirement for superior datasets the interpretability of AI algorithms and clinical integration. However, improvements in AI are set to make GI healthcare more organised, accessible, and personalised, eventually improving patient outcomes and lowering healthcare costs.

Key words: Artificial intelligence, Gastrointestinal disease, AI algorithms, AI based treatment and diagnosis.

ABBREVIATIONS:

GI: Gastrointestinal

AI: Artificial Intelligence

CAD: Computer aided diagnosis

IBD: Inflammatory bowel disease

IBS: Irritable bowel syndrome

GERD: Gastroesophageal reflux disease

EGD: Esophagogastroduodenoscopy

CE: Capsule endoscopy

EHRs: Electronic health records

CNNs: Convolutional neural networks

SVM: Support vector machine

RNNs: Recurrent neural networks

NLP: Natural language processing

RL: Reinforcement learning

ML: Machine learning

NER: Named entity recognition

FDA: Food and drug administrations

CRC: colorectal cancer

1. INTRODUCTION

AI methods are computational techniques and algorithms that enable machines to perform tasks that typically require human intelligence. These tasks include problem-solving, learning, reasoning, perception, language understanding, and decision-making. AI methods are based on mathematical models, statistical patterns, and data-driven approaches. Computer-aided diagnosis (CAD) technologies and applications that are based on artificial intelligence (AI) in a variety of medical domains. These include diabetic retinopathy, the histologic categorisation of stomach biopsies, the diagnosis of radiation oncology, the identification of brain tumours, the classification of various skin malignancies, and endoscopy [32].

Gastrointestinal (GI) diseases refer to any disorders affecting the digestive system, which includes the esophagus, stomach, intestines (small and large), liver, pancreas, and gallbladder. An illustration of GI tract is shown in figure no:1.1. These diseases range from mild conditions to severe conditions such as GI cancer, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) [38]. Some of the most common examples of GI disorder is mentioned in table 1.1 along with its symptoms [31].

Management of GI disorder:

Lifestyle modifications can play a significant role in managing GI diseases, like following proper diet, regular exercise with adequate sleep, limit alcohol and avoid excessive caffeine.

The timely diagnosis and treatment of GI diseases is critical for improving health outcomes, preventing complications, and minimizing healthcare costs. Failure to diagnose and treat these

conditions early can lead to disease progression, worsening symptoms, and even death in severe cases [7]. Hence timely diagnosis and treatment of GI diseases is essential for improving patient outcome to prevent disease progression. Screening programs, advanced diagnostic techniques, and early therapeutic interventions contribute to better survival rates and overall quality of life for patients with GI conditions. Table 1.2 shows the growth of AI in GI disease diagnosis and treatment.

2. CONVENTIONAL DIAGNOSIS AND AI BASED DIAGNOSIS METHOD AND ITS TREATMENT METHODS

Conventional methods for the diagnosis and treatment of GI diseases have been the backbone of gastroenterology for decades and these methods involves well established techniques are shown in table 2.1. Further the comparison between conventional methods and AI-based methods in the diagnosis and treatment of GI disease highlights significant differences in approach, accuracy, efficiency and limitations are shown in table 2.2 an analysis of the two, providing insight into how AI-based methods can complement or improve upon conventional techniques.

3. ARTIFICIAL INTELLIGENCE (AI)-BASED DIAGNOSIS METHODS IN GASTROINTESTINAL DISEASE

AI-based methods are increasingly applied in the GI disease diagnosis and treatment, offering significant advancements in accuracy, efficiency, and personalized treatment approaches. Below are some AI-based applications in GI disease diagnosis and treatment,

In Endoscopy and Colonoscopy, AI-powered systems, particularly those using computer vision, can analyse endoscopic and colonoscopy images to detect early-stage colorectal cancer, polyps, and other GI abnormalities with high sensitivity and specificity. AI can identify lesions that may be missed by human endoscopists, enhancing diagnostic accuracy [27]. The non-invasive technique, capsule endoscopy is used to visualize the GI tract. AI algorithms help automatically detect abnormalities such as bleeding, ulcers, and tumours by analysing the thousands of images generated during the procedure, reducing the workload for physicians and increasing diagnostic accuracy [28].

Barrett's esophagus is a condition that occurs when the lining of the lower esophagus changes due to damage from stomach acid. AI models have been developed to assist in the early detection of Barrett’s esophagus, a precancerous condition that can lead to esophageal cancer. AI helps in identifying minute changes in the esophageal lining, improving early diagnosis and enabling timely intervention [12].

AI algorithms help in predicting disease exacerbation, optimizing treatment plans, and assessing patient responses to therapies in conditions such as Crohn’s disease and ulcerative

colitis. By analysing large datasets from electronic health records (EHRs), AI identify the patterns to predict disease progression and treatment outcomes [39]. The AI model, Machine learning models have been used to predict the risk of gastrointestinal bleeding in patients, especially those on anticoagulant or antiplatelet therapies. These models assist clinicians in balancing the risk of bleeding with the need for therapy, leading to better patient management [20]. AI is increasingly used in robotic-assisted surgeries, such as GI resections or bariatric surgery, improving precision and reducing complications. AI systems assist surgeons by providing real-time feedback and guidance during procedures [32]. The Personalized Nutrition for GI disease patient, AI provides personalized dietary recommendations for patients with GI conditions, such as irritable bowel syndrome (IBS) and celiac disease. By analysing patient data and offers customized diet plans that improve symptoms and improve quality of life [47]. AI model predicts the outcomes of GI surgeries, such as patient recovery times, complication risks, and long-term prognosis. By analysing patient histories and surgical data, these models help surgeons plan more effective interventions [23]. In Pathology of GI Diseases, AI algorithms are used to analyse histopathological slides and biopsy samples, aiding pathologists in diagnosing conditions in GI tract disorders and it improves the speed and accuracy of pathological evaluations [6].

An AI algorithm is a sequence of steps or rules that computers follow to process data, recognize patterns, and make decisions or predictions. In AI, algorithms power the decision-making or learning processes that enable computers to tackle tasks that typically require human intelligence. AI algorithms play a transformative role in GI disease diagnosis by aiding clinicians with faster and more accurate detection, staging, and classification of GI diseases. Here are some primary types of AI algorithms used in this domain,

Convolutional Neural Networks (CNNs) are used in analysing endoscopic and imaging data for GI diseases. They can detect polyps, identify inflammation, and assess other abnormalities from colonoscopies, CT scans, or MRI images. [26]. CNN-based algorithms are extensively used in real-time polyp detection during colonoscopy procedures. These models analyse frames from endoscopic video feeds, automatically identifying and localizing polyps that may be indicative of colorectal cancer [32]. Support Vector Machines (SVM) are used for classification tasks in GI disease diagnosis, such as distinguishing between benign and malignant tumours or different types of lesions. SVMs can be applied to features extracted from medical images to help classify stages of diseases like esophageal cancer [43]. In Barrett's oesophagus, SVMs help in distinguishing between different stages of cellular dysplasia, thus supporting early intervention in esophageal cancer [4]. The random forest AI algorithm is a type of ensemble learning, are effective in analysing structured clinical data, such as patient demographics, lab tests, and lifestyle factors, to predict risks for diseases like inflammatory bowel disease (IBD) and assess disease severity [41]. Random forest algorithms, which aggregate the predictions of multiple decision trees, have been used to assess the activity of inflammatory bowel disease (IBD). They help in analysing various clinical, genetic, and lifestyle factors to predict the cause or remission in IBD patients [13].

Recurrent Neural Networks (RNNs) are used for analysing time-series data, making them valuable in predicting disease progression in chronic GI conditions like Crohn's disease. They can assess the longitudinal changes in patient data, offering insights into treatment effectiveness [49]. RNNs, which are ideal for sequential data, are used to model disease progression by analysing time-series data from patient's clinical records, RNNs can predict future disease activity and inform treatment planning [3]. Natural Language Processing (NLP) Algorithms are techniques that extract and analyse the information from clinical notes and EHRs, helping identify patterns in patient history relevant to GI diseases [3]. NLP algorithms can process unstructured data from electronic health records (EHRs) to extract relevant information about GI symptoms, treatments, and diagnoses. This can support clinical decision-making and streamline the diagnosis process for GI diseases [35]. Bayesian networks are used in probabilistic reasoning to model uncertainties in disease diagnosis and progression. They are useful for risk assessment and predicting the likelihood of GI disease based on multiple factors [16]. Bayesian networks provide probabilistic reasoning to estimate the likelihood of colorectal cancer in patients based on risk factors, including genetics, age, and lifestyle. This can guide clinicians in early screening and personalized monitoring [48].

4. AI ALGORITHMS FOR GASTROINTESTINAL DISEASE TREATMENT

AI algorithms support GI disease treatment by helping personalize therapies, predict patient outcomes, and optimize treatment plans. Below are some AI algorithms used specifically for GI disease treatment, along with an explanation of how these algorithms function.

Predictive Modelling Algorithms for Treatment Response [24]

The predictive modelling algorithm analyse the patient data, including clinical history, genetic markers, and lab test results, to determine the prospect of treatment success. This information supports clinicians in selecting optimal therapies for individual patients. Logistic regression, support vector machines (SVMs), and random forests are used to predict the treatment response in specific treatments like immunotherapy or chemotherapy in patients with GI disease.

Reinforcement Learning (RL) for Optimizing Treatment Plans [45]

In RL, an AI model trained by interacting with patient health status and patient data. The RL can adjust dosages and medications for IBD patients based on response to previous treatments, potentially reducing symptoms and side effects over time. RL algorithms, including

Q-learning and deep Q-networks, are used to create adaptive treatment plans that evolve based on real-time patient responses.

Natural Language Processing (NLP) for Treatment Insights from Clinical Data [35]

NLP processes are unorganized text data to identify key details on past treatment outcomes, patient symptoms, or adverse reactions. These insights assist healthcare practitioners to adjust treatment procedures and make better decisions by allowing them to evaluate previous effective medicines in comparable circumstances. These techniques, such as named entity recognition (NER) and text classification, extract and analyse treatment-related information from EHRs and clinical notes.

Bayesian Networks for Probabilistic Treatment Decision-Making [16]

Bayesian networks generate predictive models to evaluate outcomes based on variable interactions, assisting doctors in determining the possibility of treatment success or recurrence. This leads to more informed and individualized care plans. Bayesian networks assess treatment risks and benefits, considering individual patient characteristics like age, lifestyle, and genetic predispositions. They are used in conditions like colorectal cancer and liver disease to predict recurrence risk and inform post-treatment follow-ups.

Deep Learning (DL) for Drug Discovery and Precision Therapy [2]

Deep learning algorithms analyse large datasets, like genomic data and patient health records, to identify new therapeutic targets and predict patient-specific drug responses. This approach is particularly useful for complex GI diseases requiring personalized treatments, such as Crohn's disease or GI cancers. In deep learning algorithms, Convolutional neural networks (CNNs) and recurrent neural networks (RNNs) are used in drug discovery to predict therapeutic efficacy, analyse potential side effects, and optimize dosage for GI conditions.

5. CHALLENGES IN AI-BASED GASTROINTESTINAL DISEASE DIAGNOSIS AND TREATMENT

A challenge refers to a barrier or limitation that hinders the successful development, deployment, or effectiveness of the model. These challenges impact the accuracy, reliability, interpretability, and ethical use of AI, especially in sensitive fields like healthcare.

The high-quality and well-annotated datasets are essential for training robust AI models. However, GI disease data can be limited due to small sample sizes, variability in imaging (e.g., endoscopy, colonoscopy), and diverse patient demographics [19]. AI models trained on data from specific regions or demographics may struggle to generalize across different populations, potentially leading to inaccurate diagnoses and treatment recommendations for underrepresented groups [42]. Most AI models, especially deep learning ones, act as "black boxes," providing little transparency in how they reach their conclusions. This lack of interpretability can hinder clinician trust, as GI specialists need explanations of AI-derived diagnoses or recommendations [21]. In regulatory standards for clinical use, AI

solution involves rigorous validation processes to prove safety and efficacy. Additionally, privacy and ethical concerns arise around sensitive patient data used in AI training [40]. AI tools need to integrate smoothly into clinical workflows and hospital IT systems. Poor integration can disrupt workflow efficiency, reducing the potential benefits of AI and leading to clinician reluctance [10]. Implementing AI solutions often requires significant upfront investment, as well as resources for maintenance and regular updates. These costs can be prohibitive, especially for smaller healthcare facilities [8].

STRATEGIES TO OVERCOME CHALLENGES

Overcoming challenges in AI-based gastrointestinal (GI) disease diagnosis and treatment requires strategic approaches addressing data quality, interpretability, regulatory hurdles, and clinical integration. Here are some strategies with standard references to improve the adoption and effectiveness of AI in GI healthcare.

To Improve the data quality and quantity by collaborating institutions and countries to create large, diverse, and standardized datasets for AI training. Using federated learning, which enables AI models to learn from decentralized data without sharing sensitive information, can enhance data diversity and protect patient privacy [9]. Developing interpretable AI models to provide transparent, understandable results, helping clinicians make informed decisions. Techniques like explainable AI (XAI) can provide visualizations or feature importance scores, allowing healthcare providers to better understand model predictions [21]. To avoid bias, train models on diverse datasets that represent different demographics, and continuously validate models across multiple healthcare settings. Employing bias detection algorithms and evaluating model performance across subgroups can also help in minimizing bias [17]. Work with regulatory bodies early in the AI development process to ensure compliance with standards, such as FDA guidelines, and develop clear protocols for data privacy and security. Establishing ethics committees within AI research teams can further guide ethical considerations and patient consent. [5]. Design AI models that integrate seamlessly into clinical systems, such as electronic health records (EHRs), with minimal disruption to workflows. Involve clinicians in the AI design and testing phases to ensure usability and relevance to real clinical scenarios [10]. Utilization of cloud-based AI services and open-source tools reduce costs associated with model training and maintenance. Additionally, focus on creating modular AI solutions that can be adapted to facilities with different budgetary and infrastructure constraints [8].

6. FUTURE OF AI IN GASTROINTESTINAL DISEASE DIAGNOSIS AND TREATMENT

Promising developments in accuracy, effectiveness, and individualised care are anticipated in the use of AI in the diagnosis and treatment of GI disorders. According to recent studies and advancements, AI is revolutionising GI healthcare in the following important areas:

1. AI in Endoscopy and Imaging for Early Detection [29]

AI algorithms, especially deep learning, have demonstrated high accuracy in detecting early-stage cancers and precancerous lesions. AI-assisted colonoscopy, for instance, has improved polyp detection rates by analysing real-time endoscopic images. Automated image analysis helps reduce diagnostic variability and minimize human error, leading to higher detection rates for various GI conditions.

2. AI in Risk Prediction and Personalized Screening [26]

Machine learning algorithms can assess individual risk for GI diseases like colorectal cancer (CRC) by analysing data from EHRs and genetic profiles, assisting in the timely screening of high-risk patients. Based on individual risk profiles, AI tool helps for screening intervals, potentially reducing unnecessary procedures while maintaining high detection accuracy.

3. AI in Personalized Treatment for Chronic GI Conditions [30]

Machine learning models can analyse large datasets, predicting responses to treatments, such as biologics for IBD. This enables healthcare providers to make personalized, evidence-based treatment plans. By analysing patient-specific factors, AI can help optimize drug choices and dosing schedules, improving outcomes and minimizing side effects.

4. Natural Language Processing (NLP) in GI Clinical Data [16]

NLP algorithms can efficiently extract structured data from clinical notes, pathology reports, and other healthcare records, facilitating rapid analysis and identification of disease patterns. AI-powered decision support systems can alert clinicians to significant trends based on historical patient outcomes, guiding diagnosis and treatment for GI diseases.

5. Remote Monitoring and Telemedicine in GI Care [22]

AI-enabled devices and apps allow patients to record symptoms remotely, with data analysed to identify early signs of disease progression, leading to timely interventions. AI systems can monitor patients' post-procedure or post-treatment, helping detect complications early and improving long-term health outcomes.

IMPLICATIONS OF AI ADVANCEMENTS IN GASTROINTESTINAL DISEASE DIAGNOSIS AND TREATMENT

AI algorithms, particularly those utilizing machine learning and deep learning, enhance the accuracy of diagnosing GI diseases by analysing medical images, pathology slides, and patient data. These technologies can assist in identifying conditions such as colorectal cancer and IBD with greater precision than traditional methods. AI can analyse genetic information and patient histories to develop personalized treatment plans and AI tools are used to optimize treatment strategies for conditions like IBD and GI cancers. AI facilitates the early detection

of GI diseases through advanced screening techniques. In stool samples analysis or in endoscopic imaging, AI models identify the early signs of cancer or other GI disorders [34].

AI-driven robotic systems enhance the precision and effectiveness of minimally invasive surgical procedures for GI diseases. These technologies can lead to better surgical outcomes and faster recovery times for patients undergoing operations such as laparoscopic resections. AI applications in telemedicine enable the remote monitoring of patients with chronic GI conditions, allowing healthcare providers to track symptoms and medication adherence more effectively. This can lead to better disease management and timely adjustments of treatment plans. [1]

7. CONCLUSION

AI is proving invaluable in the diagnosis and treatment of gastrointestinal diseases by enhancing diagnostic accuracy, enabling personalized care, facilitating early detection, improving surgical outcomes, and supporting continuous patient management. These advancements not only improve patient outcomes but also contribute to more efficient, cost-effective healthcare delivery. As AI technology develops further, its application to GI healthcare has enormous potential to revolutionise patient care by expanding access to prompt, precise, and customised care. For these advantages to be fully realised and for the management of GI diseases to continue to improve, AI must be developed and applied ethically.

The future outlook for AI in gastrointestinal disease diagnosis and treatment is promising, with potential to redefine standards in patient care. As AI algorithms continue to advance, they are likely to achieve even greater diagnostic accuracy, especially in detecting early-stage cancers and other GI diseases. Emerging technologies may enable deeper insights into disease mechanisms, paving the way for more precise and personalized treatment strategies that adapt in real-time to a patient's evolving health status. AI has the potential to transform GI healthcare, ultimately improving patient outcomes, reducing healthcare costs, and making high-quality, individualized care more accessible.

REFERENCE

1. Abadir AP, Ali MF, Karnes W, Samarasena JB. Artificial intelligence in gastrointestinal endoscopy. Clinical endoscopy. 2020 Mar 30;53(2):132-41.
2. Baigrie, R. J., et al. (1991). Comparison of laparoscopic and open cholecystectomy in 500 patients. *The Lancet*, 338(8770), 804-808. DOI: 10.1016/0140-6736(91)90674-6.
3. Beam AL, Kohane IS. Big data and machine learning in health care. Jama. 2018 Apr 3;319(13):1317-8.
4. Bejnordi BE, Veta M, Van Diest PJ, Van Ginneken B, Karssemeijer N, Litjens G, Van Der Laak JA, Hermsen M, Manson QF, Balkenhol M, Geessink O. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. Jama. 2017 Dec 12;318(22):2199-210.

5. Benjamens, S., et al. (2020). "The Role of Regulatory Science in Medical Device Development: Case Studies in Artificial Intelligence" in npj Digital Medicine provides insights into regulatory challenges AI faces in clinical settings.
6. Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam KJ, Brogi E, Reuter VE, Klimstra DS, Fuchs TJ. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nature medicine. 2019 Aug;25(8):1301-9.
7. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clinical epidemiology. 2014 Feb 4:71-80.
8. Chen, J. H., et al. (2021). "Cost-Effectiveness of Artificial Intelligence in Health Care" in Health Affairs examines financial considerations around AI technology in healthcare.
9. Chen, M., et al. (2021). "Federated Learning for Medical Imaging: Concepts, Applications, and Challenges" published in IEEE Transactions on Medical Imaging highlights federated learning's potential in overcoming data scarcity while maintaining data privacy.
10. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future healthcare journal. 2019 Jun 1;6(2):94-8.
11. De Gregorio, C., & Buccellato, F. R. (2019). Bayesian models for gastrointestinal diagnosis in clinical practice: A systematic review. *Journal of Clinical Medicine*, 8(3), 386. DOI:10.3390/jcm8030386.
12. de Groof AJ, Struyvenberg MR, van der Putten J, van der Sommen F, Fockens KN, Curvers WL, Zinger S, Pouw RE, Coron E, Baldaque-Silva F, Pech O. Deep-learning system detects neoplasia in patients with Barrett's esophagus with higher accuracy than endoscopists in a multistep training and validation study with benchmarking. Gastroenterology. 2020 Mar 1;158(4):915-29.
13. De Jong, M. J., et al. (2020). Development and validation of a patient-reported outcome measure to assess symptoms and impact of inflammatory bowel disease: The IBD-Control. *Clinical Gastroenterology and Hepatology*, 18(1), 179-187. DOI: 10.1016/j.cgh.2019.04.050
14. Dietrich, C. F., Braden, B., & Ignee, A. (2011). Improved characterisation of hepatic tumours by contrast-enhanced ultrasound. *Clinics and Research in Hepatology and Gastroenterology*, 35(7), 432-440. DOI: 10.1016/j.clinre.2011.02.005
15. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. nature. 2017 Feb;542(7639):115-8.
16. Ghazaleh, H., et al. (2020). Application of Bayesian networks in clinical decision making for personalized treatments in colorectal cancer patients. *BMC Medical Informatics and Decision Making*, 20(1), 221. DOI: 10.1186/s12911-020-01283-6
17. Gianfrancesco MA, Tamang S, Yazdany J, Schmajuk G. Potential biases in machine learning algorithms using electronic health record data. JAMA internal medicine. 2018 Nov 1;178(11):1544-7.

18. Hashimoto DA, Rosman G, Rus D, Meireles OR. Artificial intelligence in surgery: promises and perils. Annals of surgery. 2018 Jul 1;268(1):70-6.
19. Hassan, C., et al. (2020). *"Artificial Intelligence in Gastrointestinal Endoscopy: The Road Ahead"* published in *Gastroenterology* emphasizes the data challenges in GI AI research and the need for standardized, large-scale annotated datasets.
20. Herrin J, Abraham NS, Yao X, Noseworthy PA, Inselman J, Shah ND, Ngufor C. Comparative effectiveness of machine learning approaches for predicting gastrointestinal bleeds in patients receiving antithrombotic treatment. JAMA network open. 2021 May 3;4(5):e2110703-.
21. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery. 2019 Jul;9(4):e1312.
22. Jeddi Z, Bohr A. Remote patient monitoring using artificial intelligence. InArtificial intelligence in healthcare 2020 Jan 1 (pp. 203-234). Academic Press.
23. Johnson AE, Ghassemi MM, Nemati S, Niehaus KE, Clifton DA, Clifford GD. Machine learning and decision support in critical care. Proceedings of the IEEE. 2016 Jan 25;104(2):444-66.
24. Khalid, U., et al. (2020). Machine learning applications in the diagnosis and treatment of gastrointestinal diseases. *World Journal of Gastroenterology*, 26(16), 1917–1931. DOI: 10.3748/wjg.v26.i16.1917
25. Komura D, Ishikawa S. Machine learning methods for histopathological image analysis. Computational and structural biotechnology journal. 2018 Jan 1;16:34-42.
26. Kudo SE, Mori Y, Misawa M, Takeda K, Kudo T, Itoh H, Oda M, Mori K. Artificial intelligence and colonoscopy: Current status and future perspectives. Digestive Endoscopy. 2019 Jul;31(4):363-71.
27. Lau JY, Liu Y, Wu Q, Rong L, Xu W, Li X, Wong SH, Cai S, Wang J, Liu G, Ma T. Artificial Intelligence–Assisted Colonoscopy for Colorectal Cancer Screening: A Multicenter Randomized Controlled Q8 Trial Q1. Clinical Gastroenterology and Hepatology. 2022:1.
28. Leenhardt R, Vasseur P, Li C, Saurin JC, Rahmi G, Cholet F, Becq A, Marteau P, Histace A, Dray X, Sacher-Huvelin S. A neural network algorithm for detection of GI angiectasia during small-bowel capsule endoscopy. Gastrointestinal endoscopy. 2019 Jan 1;89(1):189-94.
29. Liu WN, Zhang YY, Bian XQ, Wang LJ, Yang Q, Zhang XD, Huang J. Study on detection rate of polyps and adenomas in artificial-intelligence-aided colonoscopy. Saudi Journal of Gastroenterology. 2020 Jan 1;26(1):13-9.
30. Maeda, Y., et al. (2021). "Application of artificial intelligence in inflammatory bowel disease treatment." World Journal of Gastroenterology, 27(12), 1087-1095. This study reviews the use of AI in predicting therapeutic responses in IBD patients, promoting personalized medicine.
31. Mayo Clinic. (2023). Gastrointestinal diseases overview. Mayo Clinic.
32. Misawa M, Kudo SE, Mori Y, Cho T, Kataoka S, Yamauchi A, Ogawa Y, Maeda Y, Takeda K, Ichimasa K, Nakamura H. Artificial intelligence-assisted polyp detection for colonoscopy: initial experience. Gastroenterology. 2018 Jun 1;154(8):2027-9.

33. Owais M, Arsalan M, Choi J, Mahmood T, Park KR. Artificial intelligence-based classification of multiple gastrointestinal diseases using endoscopy videos for clinical diagnosis. Journal of clinical medicine. 2019 Jul 7;8(7):986.
34. Pannala R, Krishnan K, Melson J, Parsi MA, Schulman AR, Sullivan S, Trikudanathan G, Trindade AJ, Watson RR, Maple JT, Lichtenstein DR. Artificial intelligence in gastrointestinal endoscopy. VideoGIE. 2020 Dec 1;5(12):598-613.
35. Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, Liu PJ, Liu X, Marcus J, Sun M, Sundberg P. Scalable and accurate deep learning with electronic health records. NPJ digital medicine. 2018 May 8;1(1):1-0.
36. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Official journal of the American College of Gastroenterology| ACG. 2009 Mar 1;104(3):739-50.
37. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019 Jan;25(1):44-56.
38. Tschudin-Sutter, S., Frei, R., & Wechsler, D. (2018). Pathogenesis of gastrointestinal diseases. Clinical Microbiology Reviews, 31(2), e00102-17. https://doi.org/10.1128/CMR.00102-17.
39. Waljee AK, Lipson R, Wiitala WL, Zhang Y, Liu B, Zhu J, Wallace B, Govani SM, Stidham RW, Hayward R, Higgins PD. Predicting hospitalization and outpatient corticosteroid use in inflammatory bowel disease patients using machine learning. Inflammatory bowel diseases. 2018 Jan 1;24(1):45-53.
40. Wang P, Berzin TM, Brown JR, Bharadwaj S, Becq A, Xiao X, Liu P, Li L, Song Y, Zhang D, Li Y. Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study. Gut. 2019 Oct 1;68(10):1813-9.
41. Wei, L., Jin, Z., & Yang, Z. (2020). Application of machine learning and data mining methods to medical diagnostic databases: A survey paper. Journal of Medical Systems, 44(8), 140. DOI: 10.1007/s10916-020-01575-6.
42. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, Jung K, Heller K, Kale D, Saeed M, Ossorio PN. Do no harm: a roadmap for responsible machine learning for health care. Nature medicine. 2019 Sep;25(9):1337-40.
43. Xu, H., & Zhang, Z. (2017). Application of machine learning algorithms in early diagnosis of gastrointestinal cancers. *Gastroenterology Research and Practice*, 2017, Article ID 3936816. DOI: 10.1155/2017/3936816
44. Yasaka K, Akai H, Abe O, Kiryu S. Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: a preliminary study. Radiology. 2018 Mar;286(3):887-96.
45. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nature biomedical engineering. 2018 Oct;2(10):719-31.
46. Zalis, M. E., & Hahn, P. F. (2005). Imaging of the small bowel. *Radiologic Clinics of North America*, 43(5), 861-879. DOI: 10.1016/j.rcl.2005.06.001

47. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J. Personalized nutrition by prediction of glycemic responses. Cell. 2015 Nov 19;163(5):1079-94.
48. Zhang, L., et al. (2017). Bayesian networks for risk prediction of colorectal cancer based on environmental factors and personal characteristics: A case-control study. Scientific Reports, 7, 4763. DOI: 10.1038/s41598-017-04765-w.
49. Zulqarnain F, Rhoads SF, Syed S. Machine and deep learning in inflammatory bowel disease. Curr Opin Gastroenterol. 2023 Jul 1;39(4):294-300. doi: 10.1097/MOG.0000000000000945. Epub 2023 May 8. PMID: 37144491; PMCID: PMC10256313.

Table 1.1: GI disorders with symptoms.

GI DISORDERS	SYMPTOMS
Gastroesophageal Reflux Disease (GERD)	A condition where stomach acid frequently flows back into the oesophagus.
Peptic Ulcers	Sores that develop on the lining of the stomach, small intestine, or oesophagus.
Inflammatory Bowel Disease (IBD) and Crohn's disease	It is a chronic inflammatory bowel disease and causes inflammation in the digestive tract and

	symptoms like abdominal pain, weight loss, diarrhoea and fever
Irritable Bowel Syndrome (IBS)	A functional disorder of the intestines, leading to symptoms like cramping, abdominal pain, bloating, gas, and diarrhoea or constipation.
Celiac disease	Celiac disease is an illness caused by an immune reaction to eating gluten. Causes symptoms such as diarrhoea, fatigue, weight loss, bloating or anaemia.
Gastroenteritis	It also known as the stomach flu, is a common condition that causes inflammation of the stomach and intestines with symptoms include vomiting, nausea, weight loss, cramping and clammy skin or sweating

Table 1.2 growth of AI in GI disease diagnosis and treatment.

PERIOD	MILESTONE	DESCRIPTION
1980s-1990s	Foundational research	Early research in AI diagnostics and predictive modelling, setting groundwork for future applications.
2000s	Digital Imaging & Machine Learning	Adoption of digital endoscopy and initial ML models for image pattern recognition in GI.
2010s	Deep Learning & Big Data	Growth of neural networks, large GI image datasets, and first FDA-approved AI tools for colonoscopy.
2020-2022	Clinical Practice Integration	Real-time AI detection of polyps in colonoscopy, early diagnosis of Barrett's oesophagus and gastric cancer.
2023	Personalized Medicine & Predictive Analytics	AI-driven precision treatments for IBD and GI cancers, popularization of symptom-tracking wearables.

Table 2.1: conventional methods in diagnosis of GI disease.

S.NO	DIAGNOSIS METHOD	MECHANISM	LIMITATIONS
1	Endoscopy [9]	Visual examination of the upper/lower GI tract like oesophagus, stomach, and duodenum.	Invasive, require sedation, and depend on the skill of the endoscopist.
2	Colonoscopy [9]	Examination of the colon and rectum.	Require sedation and involves restricted diet. Colonoscopy might not detect all small polyps and cancers.
3	Barium studies (X-rays) [10]	Swallowing barium to visualize GI tract.	The risks of a barium swallow test may include problems from radiation exposure, birth defects and intestinal issues.
4	Ultrasound [11]	Imaging internal organs.	Ultrasound is operator-dependent, and its effectiveness may be limited by the patient's body habitus (e.g., obesity), as it cannot penetrate air-filled or bone structures.
5	CT/MRI scans [10]	Detailed cross-sectional imaging.	CT scans expose patients to radiation, while MRI, although safer in this regard, can be more expensive and time-consuming.
6	Blood tests	Inflammatory markers, liver function, and nutrient deficiencies.	It may give false negative or false positive result.

7	Stool tests	Infection, inflammation, or malabsorption detection.	These tests are less sensitive than colonoscopies at detecting precancerous polyps. It may also give false-negative results or false-positive results
8	Biopsy	Tissue sampling for histological examination.	Biopsy specimens vary in size and quality, and cover a smaller area than surgical specimens.
9	Esophagogastroduodenoscopy (EGD) [9]	Upper GI tract examination.	The cost of the infrastructure and skilled personnel required for an EGD can make it expensive. EGD procedures can lead to trauma, bleeding, or perforation of the small intestinal wall.
10	Capsule endoscopy	Swallowing a camera pill to visualize the small intestine.	CE has a high rate of missing lesions in the duodenum and proximal jejunum. It takes more time to read the images.

Table 2.2 comparison between conventional and AI-based methods

S.NO	METHODS	CONVENTIONAL METHODS	AI-BASED METHOD
1.	Endoscopy [5]	Conventional endoscopy is heavily operator-dependent, leading to variable detection rates, particularly for subtle lesions.	AI-based endoscopy offers greater consistency by compensating for human error and fatigue.AI has the potential to reduce missed lesions, which are common in

			conventional methods, especially for flat or small polyps.
2.	Imaging (CT, MRI, Ultrasound) [13]	Conventional imaging is limited by human error in interpreting complex or subtle findings. AI-assisted imaging can improve diagnostic accuracy and reduce variability between radiologists.	AI systems can also process and analyse images more quickly than humans, facilitating faster diagnosis, which is particularly valuable in emergency settings.
3.	Surgical Approaches [14]	Conventional surgery remains a human-driven process, with outcomes depending on the surgeon's experience. AI-based robotic systems allow for enhanced precision, reduced human error, and more predictable outcomes, particularly in complex cases.	AI also enables remote surgery capabilities, allowing specialists to perform operations across distances.



Figure 1.1: Gastrointestinal tract



Figure 3.1: AI in diagnosis of GI disease.



Figure 3.2: Upper Endoscopy

https://www.mayoclinic.org/tests-procedures/endoscopy/about/pac-20395197



Figure 3.3: Capsule endoscopy with its procedure and advantages

https://www.manhattangastroenterology.com/procedures/small-bowel-capsule/



Figure 3.4: AI assisted robotic surgery

https://www.mitrhospital.com/robotic-surgery-benefits/